Camargo Pharmaceutical Services Acquires InSymbiosis to Enhance Drug Development Capabilities

VCBeat (WeChat ID: vcbeat) learned from foreign media that on June 13, U.S. pharmaceutical services company Camargo Pharmaceutical Services (hereinafter referred to as “Camargo”) announced the acquisition of Canadian pharmaceutical company InSymbiosis. Reportedly, this acquisition was announced following Camargo’s release of its expansion strategy, through which the company plans to enhance its global presence via acquisitions. The specific financial terms of the transaction were not disclosed.

InSymbiosis, established in 2005 and headquartered in Montreal, Quebec, Canada, is a biopharmaceutical contract research organization. The company primarily provides preclinical drug development services to biopharmaceutical firms, including drug target cloning, high-throughput screening, custom gene targeting, and phenotypic analysis. Focusing on diseases across multiple therapeutic areas such as oncology, immunological disorders, metabolism, gastrointestinal conditions, and ophthalmology, InSymbiosis is dedicated to transforming the way biopharmaceutical companies outsource their R&D activities. Its team comprises a multidisciplinary drug development group, financial investment experts, and experienced project managers.

Dr. Dean Wenham, CEO of InSymbiosis, stated, “Our original intention in establishing InSymbiosis was to foster symbiotic relationships within the healthcare sector and advance pharmaceutical development. Following this acquisition, we will collaborate with Camargo to strengthen our capacity to develop these relationships and provide our clients with optimized development programs.”

Camargo Pharmaceutical Services, established in 2003, is a pharmaceutical services company specializing in drug development services for biotechnology and biopharmaceutical companies, headquartered in Cincinnati, Ohio, USA. Through innovative solutions, the company accelerates the research and development of cost-effective therapies for its clients and enhances the likelihood of their therapies gaining approval from relevant regulatory agencies, such as the FDA. Currently, Camargo’s global operations and client base have expanded to more than 25 countries worldwide.

“Meeting clients’ R&D needs and providing patients with therapies that can improve their lifestyles as soon as possible has always been Camargo’s goal,” said Dan Duffy, CEO of Camargo. “InSymbiosis offers satisfactory solutions for clients seeking to optimize their non-clinical or clinical development programs. Combined with Camargo’s expertise in drug development strategy and regulatory services, this acquisition will accelerate our ability to deliver industry-leading, integrated drug development solutions to global pharmaceutical and biotechnology companies.”

(Compiled by Wang Chan)